Orthovita reports positive data from Cortoss clinical studies
22 September 2010 00:00 in Medical Company Product News
Orthovita has published new data from clinical pilot studies which support the safety and effectiveness of its Cortoss bone augmentation material.
Results from the two multi-centre studies were published in the medical journal Spine this month, showing that Cortoss is able to provide pain relief and quality of life improvements to patients with osteoporotic vertebral compression fractures (VCFs).
These findings were reflected among patients receiving the material via both the vertebroplasty and kyphoplasty techniques of vertebral augmentation, with vertebroplasty requiring 50 per cent less material volume.
Dr Hyun Bae of The Spine Institute at Saint John's Health Center in Santa Monica, the lead author of the report, said: "These positive results formed the motivation and justification for us to continue to evaluate Cortoss in these patients."
This comes after Orthovita highlighted data presented by the Lancet last month, which underlined the advantages in pain relief terms of using vertebroplasty in the treatment of acute VCFs among elderly patients.
Other news stories from 22/09/2010
Recent news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
